Mesothelioma

Suberoylanilide Hydroxamic Acid News

Top 5 Viable New Cancer TreatmentsWednesday, April 16, 2008 @ 10:07AMKanzius RF Therapy for treating cancer is generating national-level buzz. But five other new cancer treatments could work better.

The Good And Bad Side Of Anti-cancer CompoundsSunday, April 13, 2008 @ 6:23PMTwo recent studies provide a potential mechanism by which investigational anti-cancer compounds known as HDAC inhibitors specifically damage cancer cells as well as clues about possible adverse effects of these compounds -- findings with important implications for their clinical use as cancer therapies.

Researchers reveal the good and bad side of anti-cancer compoundsFriday, April 11, 2008 @ 5:45PMWashington, Apr 11 : Researchers at Vanderbilt-Ingram Cancer Center have found that compounds known as "HDAC inhibitors," not only exhibit cancer-killing activities in cultured cells, but may also result in some adverse effects.

Anti-Cancer Compounds: The Good And The Bad SideFriday, April 11, 2008 @ 4:14AMCompounds known as "HDAC inhibitors" exhibit cancer-killing activities in cultured cells. While they are currently being tested as anti-cancer agents in clinical trials, just how they execute their effects is unclear.

The good and bad side of anti-cancer compoundsThursday, April 10, 2008 @ 10:42AMCompounds known as “HDAC inhibitors” exhibit cancer-killing activities in cultured cells. While they are currently being tested as anti-cancer agents in clinical trials, just how they execute their effects is unclear.

Dacogen(R) (Decitabine) for Injection Data Presented at the American Society of Hematology (ASH) 49th Annual Meeting ...Monday, December 10, 2007 @ 3:33PMMGI PHARMA, INC. (10197;NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today

Dacogen(R) (Decitabine) for Injection Data Presented at the American Society of Hematology (ASH) 49th Annual Meeting ...Monday, December 10, 2007 @ 3:29PMMGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today provided a summary of the Dacogen® (decitabine) for Injection presentations made during the American Society of Hematology ...

Dacogen(R) (Decitabine) for Injection Data Presented at the American Society of Hematology (ASH) 49th Annual Meeting ...Monday, December 10, 2007 @ 3:26PM ATLANTA----MGI PHARMA, INC. , a biopharmaceutical company focused in oncology and acute care, today provided a summary of the Dacogen® for Injection presentations made during the American Society of Hematology 49th Annual Meeting and Exposition.